Riskpilot← Back to searchSign inGet full accessChemoform Scandinavia AB
ABActiveOrg 5566780465Tuna Industriväg 35Wholesale of chemical products · NACE 4685Est. 200510-19 employees
Revenue 2024
SEK 73M
-1% vs 2023
EBITDA margin
-0.9%
+86% vs 2023
Equity ratio
34.7%
Financial strength
Net profit 2024
SEK -2M
+41% vs 2023
| Revenue | SEK 73M | -1% |
| EBITDA | SEK -624K | +86% |
| Net profit | SEK -2M | +41% |
| Total assets | SEK 44,5M | -3% |
| Equity | SEK 15,4M | -11% |
| Employees | — | — |
Legal name
Chemoform Scandinavia AB
Org number
5566780465
Legal form
Aktiebolag
NACE code
4685 · Wholesale of chemical products
Founded
15 mars 2005
Share capital
SEK 1 000 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-10-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall äga och förvalta lös och fast egendom, bedriva ekonomikonsultationer, managementverksamhet, investera i onoterade och noterade aktier samt därmed förenlig verksamhet.
Address
Tuna Industriväg 35
Phone
+46855922055
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 70 898 | 115 248 | 104 027 | 73 626 | 72 950 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 7 174 | 12 919 | 10 642 | −4 547 | −624 |
| Depreciation & amort. | −223 | −299 | −249 | −204 | −245 |
| EBIT | 6 951 | 12 620 | 10 393 | −4 751 | −869 |
| Net financials | −1 753 | −732 | −655 | −9 072 | −1 101 |
| Profit before tax | 4 699 | 8 188 | 8 808 | −3 314 | −1 969 |
| Tax | −1 032 | −1 758 | −1 898 | −0 | −0 |
| Net profit | 3 667 | 6 430 | 6 910 | −3 314 | −1 969 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 21 764 | 34 742 | 51 749 | 45 851 | 44 464 |
| Equity | 7 379 | 13 809 | 20 719 | 17 406 | 15 436 |
| Long-term debt | 2 145 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 860 | 15 854 | 25 020 | 28 445 | 29 028 |
| Total debt | 13 005 | 15 854 | 25 020 | 28 445 | 29 028 |
EBITDA margin
-0.9%
This company
15.8%
Market median
-106% vs market
20202024
Equity ratio
34.7%
This company
38.2%
Market median
+9% vs market
20202024
Return on equity
-12.8%
This company
18.4%
Market median
-170% vs market
20202024
Net profit margin
-2.7%
This company
8.1%
Market median
-133% vs market
20202024
Asset turnover
1.64×
This company
1.12×
Market median
+46% vs market
20202024
Debt / equity
1.88×
This company
0.62×
Market median
-203% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-11-01 – 2022-10-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-10-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-11-01 – 2020-10-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Audit | 2022 | |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHEMOFORM AG
Chemoform Scandinavia AB (this company)Board members of Chemoform Scandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Ulrika Elisabeth Westerlund | Audit | 0 companies |
| Cedrik André Mayer-Klenk | Board of Directors | 0 companies |
| Endre Winsents | Deputy Board Member | 0 companies |